Zymeworks Inc. Common Shares (ZYME) News
Filter ZYME News Items
ZYME News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
ZYME News Highlights
- For ZYME, its 30 day story count is now at 2.
- Over the past 11 days, the trend for ZYME's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- DEC, PAR and PRE are the most mentioned tickers in articles about ZYME.
Latest ZYME News From Around the Web
Below are the latest news stories about ZYMEWORKS INC that investors may wish to consider to help them evaluate ZYME as an investment opportunity.
Small-Cap Sensations: 3 Stocks Predicted for Massive Growth in 2024These three small-cap stocks have massive return potential in 2024 and beyond, according to analyst forecasts and broader industry trends. |
Zymeworks Announces $50 Million Private Placement to EcoR1 CapitalProceeds expected to extend cash runway into H2 2027VANCOUVER, British Columbia, Dec. 26, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biopharmaceutical company developing novel, multifunctional biotherapeutics, today announced that it had entered into a securities purchase agreement with funds affiliated with EcoR1 Capital, LLC (“EcoR1 Capital”), for the sale of an aggregate of 5,086,521 pre-funded warrants to purchase 5,086,521 shares of common stock, $0.00001 par v |
From $10k to $100k in 5 years: 3 Small-Cap Stocks to Make a FortuneAre you looking for small-cap stocks to get rich? |
Want to Turn Spare Change Into $1,000? Buy These 3 Stocks NowThree high conviction stocks seem perfect for opportunistic investors and could quickly transform spare change into four-figure returns. |
Zymeworks Added to Nasdaq Biotechnology IndexVANCOUVER, British Columbia, Dec. 15, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced it is expected to be added to the Nasdaq Biotechnology Index (Nasdaq: NBI) (the “NBI”). Zymeworks’ addition to the NBI will become effective prior to the market open on Monday, December 18, 2023. The NBI is designed to track the performance of a set of securities listed on The Nasdaq Stock Market th |
Next Wave Biotech: 3 Stocks Poised for Breakthrough SuccessThe overall sector may be struggling after COVID, but there's still great potential in these three biotech stocks. |
The 7 Best Bargain Growth Stocks to Buy Before 2024These bargain growth stocks offer significant upside potential alongside decent margins of safety, for those seeking impressive value. |
3 Beaten-Down Stocks to Buy for 1,000% Upside in Five YearsMany stocks now trade at tempting valuations, and these three beaten-down stocks could soar 1,000% within five years. |
Zymeworks Announces Participation in Upcoming Investor ConferenceVANCOUVER, British Columbia, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced that management will participate in an upcoming investor conference: 42nd Annual J.P. Morgan Healthcare Conference: Zymeworks’ management will participate in one-on-one meetings on January 8-11, 2024 and a corporate presentation on January 11th, 2024 at 8:15 am Pacific Time. The presentation and web |
7 Healthcare Stocks That Are Poised to Become the Next UnicornsDiscover healthcare stocks with remarkable potential for growth and "unicorn" status in the ever-evolving world of healthcare investments. |